Genmab Reports 28.2-Month Median Overall Survival in Phase 2 Trial
Genmab reported a 28.2-month median overall survival with a petosemtamab combination in a Phase 2 trial.
Genmab reported a 28.2-month median overall survival with a petosemtamab combination in a Phase 2 trial.